Insider- Cassava Sciences director buys $860K in common stock 16:24 SAVA In a regulatory filing, Cassava Sciences disclosed that director Richard Barry bought 36.16K shares of common stock on August 23rd in a total transaction size of $860.2K. Possible Gummy Tomm- Cassava Sciences, Inc. (SAVA) NasdaqCM - NasdaqCM Real Time Price. Currency in USD 27.28-0.55(-1.98%) At close: 04:00PM EDT 29.22+1.94(+7.11%)<------- up 7% After hours:05:06PM EDT
Insider buy. The Wolf! $240K https://www.sec.gov/Archives/edgar/...00059/xslF345X03/wf-form4_166145904911138.xml
Van you are not going to have to worry about Seeking Alpha anymore. Apparently i have reached my limit on free articles. I can't get anything from this bastard site now. What a joke. First they tricked me into signing in as if that would change anything stole whatever they could off that stupid move.. signed in with my Apple ID so they are probably clawing all around my personal shit now. An attack against the stoned investor by Seeking Alpha.. I won't forget... More CRISPR In Human Subjects- Would of loved to have read this article. Jul. 14, 2022 1:09 PM ETVerve Therapeutics, Inc. (VERV)1 Comment7 Likes Summary Verve Therapeutics has started a trial using CRISPR base editing technology to modify the PCSK9 gene in people with a disease called heterozygous familial hypercholesterolemia (HeFH). Familial hypercholesterolemia, for its part, is pretty much what the name implies: an inherited genetic disorder that leads to high levels of cholesterol, specifically high LDL levels. But regardless of the reason for high LDL, taking out PCSK9 function should increase expression of LDL receptors and thus lead to lower circulating levels of LDL itself.
Verve upgraded to Buy at Stifel on near term catalysts for heart disease therapy-- Big Pete used to work at Stifel I can check on this analyst. This is regarding VERV-101. Verve Therapeutics upgraded to Buy at Stifel on upside from near-term catalysts 16:54 VERV Stifel analyst Dae Gon Ha upgraded Verve Therapeutics to Buy from Hold with a price target of $56, up from $32. The analyst was previously cautious on uncertain risk-benefit analysis of VERVE-101 by the FDA and market receptivity, if approved, but now he believes that catalysts like VERVE-101 IND and its clinical data will drive Verve Therapeutics shares. Ha adds that even under a bear case of no IND for VERVE-101, NTLA-2001 precedent suggests that positive Phase 1 heart-1 data may present meaningful upside from current levels. As well) Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate Aug. 23, <------2022 3:57 PM ET Verve Therapeutics, Inc. (VERV) Shares of Verve Therapeutics are up 13% in late Tuesday afternoon trading following the release of preclinical data on VERVE-201 for a type of genetically high cholesterol(homozygous familial hypercholesterolemia). VERVE-201 <--------- Ok the nice thing about these gene platform stocks is if they hit one of their lead compounds they are probably going to hit the other using same methods. $293 mil cash. Spot secondary at $27 led to......STOCK EXPLODING UP! CEO of Verve Therapeutics Sekar Kathiresan then sells $1.5M in shares 07/21 VERV The CEO of Verve Therapeutics Sekar Kathiresan disclosed in a filing that he sold 50,000 shares of company stock at $29.90 per share on July 19, for a total transaction amount of $1,495,000. SELL at $29??? <----------- Estimated short interest in Verve Therapeutics (VERV) was down over three percentage points to 35.6% - the lowest level since early May. The stock has doubled in the span of two weeks after raising $400M in capital at the start of the month and then announcing the dosing of its first patient in the Verve-101 study on July 12. Verve Therapeutics, Inc. (VERV) NasdaqGS - NasdaqGS Real Time Price. 41.31+1.19(+2.97%) At close: 04:00PM EDT Conflicted. This is probably going much higher but I don't like that Insider sell.
Shroom stock! Mind Medicine initiated with an Outperform at Oppenheimer 16:05 MNMD Oppenheimer analyst…
A millennial who paid off $100K in student loans just months before Biden announced forgiveness says the president should ‘forgive all of it’